When it comes to advanced scientific degrees, we field the largest biotechnology group in New England — 37 members, over 80% of whom have PhDs or MDs. We aggressively recruit people who develop advanced technology, and who speak the language of inventors and scientists, quickly grasping complex biotechnology matters.
"They can come through on any technology; I’ve tested them on that. I have a good set of experience with other firms, and Wolf Greenfield has the depth and breadth."
Our clients include both large and emerging biotech companies such as Biogen, Dyax Corporation, and Lantheus Medical Imaging, privately financed startup companies, and prestigious academic and research institutions, including MIT, Dana Farber Cancer Institute, and Harvard Medical School. We understand the different needs of each client and bring practical solutions to the table.
"I don’t know that I’ve seen any other law firms produce anything better. Top quality, and they are able to act as business strategists as well."
Our experience is broad and deep, covering areas from antibodies to transgenic technologies—and everything in between. We also call on members of our other practice groups including Chemical & Materials Technologies and Pharmaceutical when their specialized knowledge will benefit a client’s project. In addition, our teams routinely include support from our paralegal group and our International Filing Department to contain costs and deliver value.
"The reputation is that they can handle complex matters very efficiently. In my experience, that is true. When there were some difficult or technical cases, I have gone to Wolf Greenfield."
Our group's services include: IP strategic planning; patent portfolio development, acquisition, and enforcement; studies on patentability, infringement, and validity; IP audits and due diligence; licensing and technology transfer; defending and challenging patent validity, including post-grant proceedings; and freedom to operate and competitor analyses.
"Wolf Greenfield has the ability to create IP opportunities for us that are worth millions."